Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Agasta Software is engaged in research, development and commercialization of medical devices
Subscribe To Our Newsletter & Stay Updated
